Abbott Biotech Ventures, one of the corporate venturing funds run by pharmaceutical corporation Abbott Laboratories, invested an undisclosed amount in US-based Alzheimer’s disease therapeutics company NeuroGenetic Pharmaceuticals (NGP) on Wednesday. Founded in 2009, NeuroGenetic’s technology is based around a compound, NGP555, that it claims can detect and reduce the brain plaques associated with Alzheimer’s. The…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
